-
3
-
-
77952773418
-
VHL and HIF signalling in renal cell carcinogenesis
-
Baldewijns MM, van Vlodrop IJH, Vermeulen PB, Soetekouw PMMB, van Engeland M, de Bruïne AP. VHL and HIF signalling in renal cell carcinogenesis. J Path 2010;221: 125-38.
-
(2010)
J Path
, vol.221
, pp. 125-138
-
-
Baldewijns, M.M.1
Van Vlodrop, I.J.H.2
Vermeulen, P.B.3
Soetekouw, P.M.M.B.4
Van Engeland, M.5
De Bruïne, A.P.6
-
4
-
-
0036242160
-
Expression of HGF/SF and Met protein is associated with genetic alterations of VHL gene in primary renal cell carcinomas
-
Oh RR, Park JY, Lee JH, Shin MS, Kim HS, Lee SK, et al. Expression of HGF/SF and Met protein is associated with genetic alterations of VHL gene in primary renal cell carcinomas. Acta Pathol Microbiol Immunol Scand 2002;110: 229-38.
-
(2002)
Acta Pathol Microbiol Immunol Scand
, vol.110
, pp. 229-238
-
-
Oh, R.R.1
Park, J.Y.2
Lee, J.H.3
Shin, M.S.4
Kim, H.S.5
Lee, S.K.6
-
5
-
-
0037478437
-
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene
-
Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003;3: 347-61.
-
(2003)
Cancer Cell
, vol.3
, pp. 347-361
-
-
Pennacchietti, S.1
Michieli, P.2
Galluzzo, M.3
Mazzone, M.4
Giordano, S.5
Comoglio, P.M.6
-
6
-
-
14644440555
-
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis
-
Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23: 1011-27.
-
(2005)
J Clin Oncol
, vol.23
, pp. 1011-1027
-
-
Hicklin, D.J.1
Ellis, L.M.2
-
7
-
-
47949089077
-
VEGF-targeted therapy: Mechanisms of anti-tumour activity
-
Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nature Rev Cancer 2008;8: 579-91.
-
(2008)
Nature Rev Cancer
, vol.8
, pp. 579-591
-
-
Ellis, L.M.1
Hicklin, D.J.2
-
9
-
-
82755183572
-
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial
-
Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011;378: 1931-9.
-
(2011)
Lancet
, vol.378
, pp. 1931-1939
-
-
Rini, B.I.1
Escudier, B.2
Tomczak, P.3
Kaprin, A.4
Szczylik, C.5
Hutson, T.E.6
-
10
-
-
84876974877
-
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: Overall survival analysis and updated results from a randomised phase 3 trial
-
Motzer RJ, Escudier B, Tomczak P, Hutson TE, Michaelson MD, Negrier S, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 2013;14: 552-62.
-
(2013)
Lancet Oncol
, vol.14
, pp. 552-562
-
-
Motzer, R.J.1
Escudier, B.2
Tomczak, P.3
Hutson, T.E.4
Michaelson, M.D.5
Negrier, S.6
-
11
-
-
58149337448
-
Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3
-
Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 2008;14: 7272-83.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 7272-7283
-
-
Hu-Lowe, D.D.1
Zou, H.Y.2
Grazzini, M.L.3
Hallin, M.E.4
Wickman, G.R.5
Amundson, K.6
-
12
-
-
47949099628
-
Modes of resistance to anti-angiogenic therapy
-
Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nature Rev Cancer 2008;8: 592-603.
-
(2008)
Nature Rev Cancer
, vol.8
, pp. 592-603
-
-
Bergers, G.1
Hanahan, D.2
-
13
-
-
84866693927
-
Controlling escape from angiogenesis inhibitors
-
Sennino B, McDonald DM. Controlling escape from angiogenesis inhibitors. Nat Rev Cancer 2012;12: 699-709.
-
(2012)
Nat Rev Cancer
, vol.12
, pp. 699-709
-
-
Sennino, B.1
McDonald, D.M.2
-
14
-
-
78649420006
-
MET signalling: Principles and functions in development, organ regeneration and cancer
-
Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 2010;11: 834-48.
-
(2010)
Nat Rev Mol Cell Biol
, vol.11
, pp. 834-848
-
-
Trusolino, L.1
Bertotti, A.2
Comoglio, P.M.3
-
15
-
-
0036221263
-
Dysregulation of Met receptor tyrosine kinase activity in invasive tumors
-
Danilkovitch-miagkova A, Zbar B. Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J Clin Invest 2002;109: 863-7.
-
(2002)
J Clin Invest
, vol.109
, pp. 863-867
-
-
Danilkovitch-Miagkova, A.1
Zbar, B.2
-
16
-
-
84863754907
-
VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex
-
Lu K V, Chang JP, Parachoniak CA, Pandika MM, Aghi MK, Meyronet D, et al. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 2012;22: 21-35.
-
(2012)
Cancer Cell
, vol.22
, pp. 21-35
-
-
Lu, K.V.1
Chang, J.P.2
Parachoniak, C.A.3
Pandika, M.M.4
Aghi, M.K.5
Meyronet, D.6
-
17
-
-
84877098516
-
Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance
-
Jahangiri A, De Lay M, Miller LM, Carbonell WS, Hu Y-L, Lu K, et al. Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance. Clin Cancer Res 2013;19: 1773-83.
-
(2013)
Clin Cancer Res
, vol.19
, pp. 1773-1783
-
-
Jahangiri, A.1
De Lay, M.2
Miller, L.M.3
Carbonell, W.S.4
Hu, Y.-L.5
Lu, K.6
-
18
-
-
78650339354
-
HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors
-
Shojaei F, Lee JH, Simmons BH, Wong A, Esparza CO, Plumlee Pa, et al. HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Res 2010;70: 10090-100.
-
(2010)
Cancer Res
, vol.70
, pp. 10090-10100
-
-
Shojaei, F.1
Lee, J.H.2
Simmons, B.H.3
Wong, A.4
Esparza, C.O.5
Plumlee, Pa.6
-
19
-
-
34249324494
-
An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms
-
Zou HY, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007;67: 4408-17.
-
(2007)
Cancer Res
, vol.67
, pp. 4408-4417
-
-
Zou, H.Y.1
Li, Q.2
Lee, J.H.3
Arango, M.E.4
McDonnell, S.R.5
Yamazaki, S.6
-
20
-
-
84879071011
-
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer
-
Shaw AT, Kim D-W, Nakagawa K, Seto T, Crinó L, Ahn M-J, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. NEJM 2013;368: 2385-94.
-
(2013)
NEJM
, vol.368
, pp. 2385-2394
-
-
Shaw, A.T.1
Kim, D.-W.2
Nakagawa, K.3
Seto, T.4
Crinó, L.5
Ahn, M.-J.6
-
21
-
-
77953467629
-
Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: Evidence from a xenograft study
-
Hammers HJ, Verheul HM, Salumbides B, Sharma R, Rudek M, Jaspers J, et al. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. Mol Cancer Ther 2010;9: 1525-35.
-
(2010)
Mol Cancer Ther
, vol.9
, pp. 1525-1535
-
-
Hammers, H.J.1
Verheul, H.M.2
Salumbides, B.3
Sharma, R.4
Rudek, M.5
Jaspers, J.6
-
22
-
-
78650900647
-
ImmunoRatio: A publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67
-
Tuominen VJ, Ruotoistenmäki S, Viitanen A, Jumppanen M, Isola J. ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67. Breast Cancer Res 2010;12: R56.
-
(2010)
Breast Cancer Res
, vol.12
, pp. R56
-
-
Tuominen, V.J.1
Ruotoistenmäki, S.2
Viitanen, A.3
Jumppanen, M.4
Isola, J.5
-
23
-
-
84863704553
-
Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors
-
Sennino B, Ishiguro-Oonuma T, Wei Y, Naylor RM, Williamson CW, Bhagwandin V, et al. Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov 2012;2: 270-87.
-
(2012)
Cancer Discov
, vol.2
, pp. 270-287
-
-
Sennino, B.1
Ishiguro-Oonuma, T.2
Wei, Y.3
Naylor, R.M.4
Williamson, C.W.5
Bhagwandin, V.6
-
24
-
-
77958072683
-
Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling
-
Bhatt RS, Wang X, Zhang L, Collins MP, Signoretti S, Alsop DC, et al. Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling. Mol Cancer Ther 2010;9: 2793-802.
-
(2010)
Mol Cancer Ther
, vol.9
, pp. 2793-2802
-
-
Bhatt, R.S.1
Wang, X.2
Zhang, L.3
Collins, M.P.4
Signoretti, S.5
Alsop, D.C.6
-
25
-
-
33749441325
-
Rapid vascular regrowth in tumors after reversal of VEGF inhibition
-
Mancuso MR, Davis R, Norberg SM, O'Brien S, Sennino B, Nakahara T, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006;116: 2610-21.
-
(2006)
J Clin Invest
, vol.116
, pp. 2610-2621
-
-
Mancuso, M.R.1
Davis, R.2
Norberg, S.M.3
O'Brien, S.4
Sennino, B.5
Nakahara, T.6
-
26
-
-
0026722243
-
Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth
-
Bussolino F, Di Renzo MF, Ziche M, Bocchietto E, Olivero M, Naldini L, et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 1992;119: 629-41.
-
(1992)
J Cell Biol
, vol.119
, pp. 629-641
-
-
Bussolino, F.1
Di Renzo, M.F.2
Ziche, M.3
Bocchietto, E.4
Olivero, M.5
Naldini, L.6
-
27
-
-
3142512610
-
Targeting the tumor and its microenvironment by a dual-function decoy Met receptor
-
Michieli P, Mazzone M, Basilico C, Cavassa S, Sottile A, Naldini L, et al. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 2004;6: 61-73.
-
(2004)
Cancer Cell
, vol.6
, pp. 61-73
-
-
Michieli, P.1
Mazzone, M.2
Basilico, C.3
Cavassa, S.4
Sottile, A.5
Naldini, L.6
-
28
-
-
84862657056
-
Acquired MET expression confers resistance to EGFR inhibition in a mouse model of glioblastoma multiforme
-
Jun HJ, Acquaviva J, Chi D, Lessard J, Zhu H, Woolfenden S, et al. Acquired MET expression confers resistance to EGFR inhibition in a mouse model of glioblastoma multiforme. Oncogene 2012;31: 3039-50.
-
(2012)
Oncogene
, vol.31
, pp. 3039-3050
-
-
Jun, H.J.1
Acquaviva, J.2
Chi, D.3
Lessard, J.4
Zhu, H.5
Woolfenden, S.6
-
29
-
-
84905175125
-
A phase I study of cabozantinib (XL184) in patients with renal cell cancer
-
Choueiri T, Pal SK, McDermott DF, Morrissey S, Ferguson KC, Holland J , et al. A phase I study of cabozantinib (XL184) in patients with renal cell cancer. Ann Oncol 2014;8: 1603-8.
-
(2014)
Ann Oncol
, vol.8
, pp. 1603-1608
-
-
Choueiri, T.1
Pal, S.K.2
McDermott, D.F.3
Morrissey, S.4
Ferguson, K.C.5
Holland, J.6
|